A COST-EFFECTIVESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN PORTUGAL

被引：0
|
作者：
Silva Miguel, L. [1 ]
Pinheiro, B. [1 ]
Lopes, R. [1 ]
Revil, C. [2 ]
Monteiro, I [3 ]
Borges, M. [4 ]
机构：
[1] Univ Lisbon, Ctr Estudos Med Baseada Evidencia, Fac Med, Lisbon 11, Portugal
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Roche Farmaceut Quim Lda, Amadora, Portugal
[4] Univ Lisbon, Lab Farmacol Clin & Terapeut, Fac Med, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSB51
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer
    Guan, X.
    Li, H-C.
    Chen, Q-J.
    Hua, B.
    Li, J-J.
    Ma, F.
    Wang, Y-S.
    Xu, H.
    Liu, C.
    Yang, Q.
    Ma, A-X.
    ANNALS OF ONCOLOGY, 2021, 32 : S45 - S45
  • [2] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [3] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
    Guan, X.
    Li, H. C.
    Xia, Y.
    Yang, Q.
    Ma, A. X.
    VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
  • [4] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
    Fonseca Magalhaes Filho, Marcos Aurelio
    Aguiar, Pedro Nazareth, Jr.
    Mascarenhas Neves, Milena Brachmans
    Lopes, Gilberto de Lima, Jr.
    del Giglio, Auro
    EINSTEIN-SAO PAULO, 2022, 20 : eGS6655
  • [6] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Loibl, Sibylle
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Geyer, Charles E.
    Untch, Michael
    Thery, Jean-Christophe
    Schwaner, Ingo
    Limentani, Steven
    Loman, Niklas
    Lubbe, Kristina
    Chang, Jenny C.
    Hatschek, Thomas
    Tesarowski, David
    Song, Chunyan
    de Haas, Sanne Lysbet
    Boulet, Thomas
    Lambertini, Chiara
    Wolmark, Norman
    NPJ BREAST CANCER, 2022, 8 (01)
  • [7] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Sibylle Loibl
    Chiun-Sheng Huang
    Max S. Mano
    Eleftherios P. Mamounas
    Charles E. Geyer
    Michael Untch
    Jean-Christophe Thery
    Ingo Schwaner
    Steven Limentani
    Niklas Loman
    Kristina Lübbe
    Jenny C. Chang
    Thomas Hatschek
    David Tesarowski
    Chunyan Song
    Sanne Lysbet de Haas
    Thomas Boulet
    Chiara Lambertini
    Norman Wolmark
    npj Breast Cancer, 8
  • [8] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Katherine A. Lyseng-Williamson
    Drugs, 2020, 80 : 1723 - 1730
  • [9] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [10] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Lyseng-Williamson, Katherine A.
    DRUGS, 2020, 80 (16) : 1723 - 1730
12345